Previous 10 | Next 10 |
NEW YORK, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has recently published published CEO Interviews, video presentations, and news updates from the company’s presenting at last month’s NEXT SUPER STOCK Live! inves...
The FDA has signed off on a Phase 2 clinical trial evaluating CytoDyn's ( OTCQB:CYDY +0.2% ) leronlimab (PRO 140), combined with Bayer's Stivarga (regorafenib), in patients with metastatic colorectal cancer (mCRC). More news on: CytoDyn Inc., Healthcare stocks news, Read more ...
VANCOUVER, Washington, Sept. 09, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, a...
VANCOUVER, Washington, Sept. 06, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, a...
VANCOUVER, Washington, Sept. 04, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, a...
VANCOUVER, Washington, Aug. 29, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, an...
Phoenix, Arizona--(Newsfile Corp. - August 22, 2019) - The Stock Day Podcast welcomed CytoDyn (OTCQB: CYDY) ("the Company"), a biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CC...
Updated results from an HIV clinical trial evaluating escalating doses of CytoDyn's ( OTCQB:CYDY -0.1% ) PRO 140 (leronlimab) showed sustained viral load suppression at ~one year. More news on: CytoDyn Inc., Healthcare stocks news, Read more ...
NEW YORK, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Wall Street Reporter will be hosting the “Next Super Stock - Live !” livestream online-only investor conference on Thursday August 15, 2019 from 12:00PM-1:00PM EST. Registration is free. Click here to join: https://www.wall...
564 patients have been enrolled in monotherapy trials to date with over 150 patients hitting the benchmark of one-year of sustained viral suppression The response rate post-10 weeks of monotherapy is 68% with 350 mg dose, 94% with 525 mg and 85% with 700 mg VANCOUVER, Washington, Aug....
News, Short Squeeze, Breakout and More Instantly...
Terms of the settlement include $12,000,000 cash payment to CytoDyn and elimination of $14,000,000 accounts payable liability from the Company’s balance sheet VANCOUVER, Washington, July 09, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a bio...
VANCOUVER, Washington, June 27, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that its preclinical MASH study with SMC ...
VANCOUVER, Washington, May 28, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob P. Lalezari, Chief Executiv...